These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 34400183)

  • 1. Inhibition of N-Nitrosamine Formation in Drug Products: A Model Study.
    Nanda KK; Tignor S; Clancy J; Marota MJ; Allain LR; D'Addio SM
    J Pharm Sci; 2021 Dec; 110(12):3773-3775. PubMed ID: 34400183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Nitrite Excipient Database: A Useful Tool to Support N-Nitrosamine Risk Assessments for Drug Products.
    Boetzel R; Schlingemann J; Hickert S; Korn C; Kocks G; Luck B; Blom G; Harrison M; François M; Allain L; Wu Y; Bousraf Y
    J Pharm Sci; 2023 Jun; 112(6):1615-1624. PubMed ID: 35500671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bumetanide as a Model NDSRI Substrate: N-nitrosobumetanide Impurity Formation and its Inhibition in Bumetanide Tablets.
    Shakleya D; Asmelash B; Alayoubi A; Abrigo N; Mohammad A; Wang J; Zhang J; Yang J; Marzan TA; Li D; Shaklah M; Alsharif FM; Desai S; Faustino PJ; Ashraf M; O'Connor T; Vera M; Raw A; Sayeed VA; Keire D
    J Pharm Sci; 2023 Dec; 112(12):3075-3087. PubMed ID: 37364772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-Nitrosamine Formation in Pharmaceutical Solid Drug Products: Experimental Observations.
    Moser J; Ashworth IW; Harris L; Hillier MC; Nanda KK; Scrivens G
    J Pharm Sci; 2023 May; 112(5):1255-1267. PubMed ID: 36736774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-nitrosamine Mitigation with Nitrite Scavengers in Oral Pharmaceutical Drug Products.
    Bayne AV; Misic Z; Stemmler RT; Wittner M; Frerichs M; Bird JK; Besheer A
    J Pharm Sci; 2023 Jul; 112(7):1794-1800. PubMed ID: 37023856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trace Aldehydes in Solid Oral Dosage Forms as Catalysts for Nitrosating Secondary Amines.
    Harmon P
    J Pharm Sci; 2023 May; 112(5):1216-1219. PubMed ID: 36336102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling the Impact of Excipients Selection on Nitrosamine Formation towards Risk Mitigation.
    Berardi A; Jaspers M; Dickhoff BHJ
    Pharmaceutics; 2023 Jul; 15(8):. PubMed ID: 37631229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha-tocopherol: uses in preventing nitrosamine formation.
    Mergens WJ; Kamm JJ; Newmark HL; Fiddler W; Pensabene J
    IARC Sci Publ (1971); 1978; (19):199-212. PubMed ID: 28277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies on nitrosamine formation by the interaction between drugs and nitrite. I. Measurement of the amount of nitrosamine formed in rat and guinea pig stomachs.
    Kawanishi T; Ohno Y; Takahashi A; Ishiwata H; Tanimura A; Kasuya Y; Omori Y
    J Toxicol Sci; 1981 Nov; 6(4):261-70. PubMed ID: 7338958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parts per billion of nitrite in microcrystalline cellulose by ion chromatography mass spectrometry with isotope labeled internal standard.
    Zhu K; Kerry M; Serr B; Mintert M
    J Pharm Biomed Anal; 2023 Oct; 235():115648. PubMed ID: 37611458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of amine structural characteristics on N-nitrosamine formation potential relevant to postcombustion CO2 capture systems.
    Dai N; Mitch WA
    Environ Sci Technol; 2013 Nov; 47(22):13175-83. PubMed ID: 24138561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nitroso Impurities in Drug Products: An Overview of Risk Assessment, Regulatory Milieu, and Control Strategy.
    Charoo NA; Dharani S; Khan MA; Rahman Z
    AAPS PharmSciTech; 2023 Feb; 24(2):60. PubMed ID: 36759424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nitrosated Active Pharmaceutical Ingredients - Lessons Learned?
    Holzgrabe U
    J Pharm Sci; 2023 May; 112(5):1210-1215. PubMed ID: 36720391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Approaches to cancer prevention based on an understanding of N-nitrosamine carcinogenesis.
    Hecht SS
    Proc Soc Exp Biol Med; 1997 Nov; 216(2):181-91. PubMed ID: 9349687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of nitrosamine formation by ascorbic acid.
    Tannenbaum SR; Wishnok JS; Leaf CD
    Am J Clin Nutr; 1991 Jan; 53(1 Suppl):247S-250S. PubMed ID: 1985394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nitrosamine Impurities in Pharmaceuticals: An Empirical Review of their Detection, Mechanisms, and Regulatory Approaches.
    Bhirud D; Agrawal G; Shah H; Patel A; Palkar MB; Bhattacharya S; Prajapati BG
    Curr Top Med Chem; 2024; 24(6):503-522. PubMed ID: 38321910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of the Formaldehyde-Catalyzed NNitrosation of Dialkyl Amines: An Automated Experimental and Kinetic Modelling Study Using Dibutylamine.
    Diab S; Ferrini P; Dominey AP; Whiting MP; Wickens JR; Ashworth IW; Rainey TJ
    J Pharm Sci; 2024 Jun; 113(6):1624-1635. PubMed ID: 38307493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comprehensive review of sources of nitrosamine contamination of pharmaceutical substances and products.
    Akkaraju H; Tatia R; Mane SS; Khade AB; Dengale SJ
    Regul Toxicol Pharmacol; 2023 Mar; 139():105355. PubMed ID: 36792049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Caffeic and ferulic acid as blockers of nitrosamine formation.
    Kuenzig W; Chau J; Norkus E; Holowaschenko H; Newmark H; Mergens W; Conney AH
    Carcinogenesis; 1984 Mar; 5(3):309-13. PubMed ID: 6368031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the protective effect of ascorbic acid on nitrite- and nitrosamine-induced cytotoxicity and genotoxicity in human hepatoma line.
    Erkekoglu P; Baydar T
    Toxicol Mech Methods; 2010 Feb; 20(2):45-52. PubMed ID: 20100056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.